Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter studyMaël Heiblig, Pierre Sujobert, Mathieu Gerfaud‐Valentin et al.|Blood|2022Cited by 212
Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective StudyMaël Heiblig, Pierre Sujobert, Marcela A. Ferrada et al.|Blood|2021Cited by 12